Risk reduction of hospitalisation and severe disease in vaccinated COVID-19 cases during the SARS-CoV-2 variant Omicron BA.1-predominant period, Navarre, Spain, January to March 2022
BackgroundAs COVID-19 vaccine effectiveness against SARS-CoV-2 infection was lower for cases of the Omicron vs the Delta variant, understanding the effect of vaccination in reducing risk of hospitalisation and severe disease among COVID-19 cases is crucial.AimTo evaluate risk reduction of hospitalisation and severe disease in vaccinated COVID-19 cases during the Omicron BA.1-predominant period in Navarre, Spain.MethodsA case-to-case comparison included COVID-19 epidemiological surveillance data in adults ≥ 18 years from 3 January-20 March 2022. COVID-19 vaccination status was compared between hospitalised and non-hospitalised cases, and between severe (intensive care unit admission or death) and non-severe cases using logistic regression models.ResultsAmong 58,952 COVID-19 cases, 565 (1.0%) were hospitalised and 156 (0.3%) were severe. The risk of hospitalisation was reduced within the first 6 months after full COVID-19 vaccination (complete primary series) (adjusted odds ratio (aOR): 0.06; 95% CI: 0.04-0.09) and after 6 months (aOR: 0.16; 95% CI: 0.12-0.21; pcomparison < 0.001), as well as after a booster dose (aOR: 0.06: 95% CI: 0.04-0.07). Similarly, the risk of severe disease was reduced (aOR: 0.13, 0.18, and 0.06, respectively). Compared with cases fully vaccinated 6 months or more before a positive test, those who had received a booster dose had lower risk of hospitalisation (aOR: 0.38; 95% CI: 0.28-0.52) and severe disease (aOR: 0.38; 95% CI: 0.21-0.68).ConclusionsFull COVID-19 vaccination greatly reduced the risk of hospitalisation and severe outcomes in COVID-19 cases with the Omicron variant, and a booster dose improved this effect in people aged over 65 years.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin - 28(2023), 5 vom: 14. Feb. |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 06.02.2023 Date Revised 05.05.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2807/1560-7917.ES.2023.28.5.2200337 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352393718 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352393718 | ||
| 003 | DE-627 | ||
| 005 | 20231226053626.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2807/1560-7917.ES.2023.28.5.2200337 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1174.xml |
| 035 | |a (DE-627)NLM352393718 | ||
| 035 | |a (NLM)36729113 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Martínez-Baz, Iván |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Risk reduction of hospitalisation and severe disease in vaccinated COVID-19 cases during the SARS-CoV-2 variant Omicron BA.1-predominant period, Navarre, Spain, January to March 2022 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.02.2023 | ||
| 500 | |a Date Revised 05.05.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BackgroundAs COVID-19 vaccine effectiveness against SARS-CoV-2 infection was lower for cases of the Omicron vs the Delta variant, understanding the effect of vaccination in reducing risk of hospitalisation and severe disease among COVID-19 cases is crucial.AimTo evaluate risk reduction of hospitalisation and severe disease in vaccinated COVID-19 cases during the Omicron BA.1-predominant period in Navarre, Spain.MethodsA case-to-case comparison included COVID-19 epidemiological surveillance data in adults ≥ 18 years from 3 January-20 March 2022. COVID-19 vaccination status was compared between hospitalised and non-hospitalised cases, and between severe (intensive care unit admission or death) and non-severe cases using logistic regression models.ResultsAmong 58,952 COVID-19 cases, 565 (1.0%) were hospitalised and 156 (0.3%) were severe. The risk of hospitalisation was reduced within the first 6 months after full COVID-19 vaccination (complete primary series) (adjusted odds ratio (aOR): 0.06; 95% CI: 0.04-0.09) and after 6 months (aOR: 0.16; 95% CI: 0.12-0.21; pcomparison < 0.001), as well as after a booster dose (aOR: 0.06: 95% CI: 0.04-0.07). Similarly, the risk of severe disease was reduced (aOR: 0.13, 0.18, and 0.06, respectively). Compared with cases fully vaccinated 6 months or more before a positive test, those who had received a booster dose had lower risk of hospitalisation (aOR: 0.38; 95% CI: 0.28-0.52) and severe disease (aOR: 0.38; 95% CI: 0.21-0.68).ConclusionsFull COVID-19 vaccination greatly reduced the risk of hospitalisation and severe outcomes in COVID-19 cases with the Omicron variant, and a booster dose improved this effect in people aged over 65 years | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a COVID-19 hospitalisation | |
| 650 | 4 | |a COVID-19 vaccine | |
| 650 | 4 | |a Omicron variant | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a severe COVID-19 | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a Trobajo-Sanmartín, Camino |e verfasserin |4 aut | |
| 700 | 1 | |a Miqueleiz, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Casado, Itziar |e verfasserin |4 aut | |
| 700 | 1 | |a Navascués, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Burgui, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Ezpeleta, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Castilla, Jesús |e verfasserin |4 aut | |
| 700 | 1 | |a Guevara, Marcela |e verfasserin |4 aut | |
| 700 | 0 | |a Working Group for the Study of COVID-19 in Navarra |e verfasserin |4 aut | |
| 700 | 0 | |a Members of the Working Group for the Study of COVID-19 in Navarra |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández-Huerta, Miguel |e investigator |4 oth | |
| 700 | 1 | |a Martín, Carmen |e investigator |4 oth | |
| 700 | 1 | |a Portillo, María Eugenia |e investigator |4 oth | |
| 700 | 1 | |a Estévez, Ingrid |e investigator |4 oth | |
| 700 | 1 | |a Tordoya, Igberto |e investigator |4 oth | |
| 700 | 1 | |a Quílez, Delia |e investigator |4 oth | |
| 700 | 1 | |a Lameiro, Francisco |e investigator |4 oth | |
| 700 | 1 | |a Álvaro, Ana Isabel |e investigator |4 oth | |
| 700 | 1 | |a Ardanaz, Eva |e investigator |4 oth | |
| 700 | 1 | |a Baigorria, Fernando |e investigator |4 oth | |
| 700 | 1 | |a Barricarte, Aurelio |e investigator |4 oth | |
| 700 | 1 | |a Egüés, Nerea |e investigator |4 oth | |
| 700 | 1 | |a Cenoz, Manuel García |e investigator |4 oth | |
| 700 | 1 | |a Iriarte, Nerea |e investigator |4 oth | |
| 700 | 1 | |a Moreno-Iribas, Conchi |e investigator |4 oth | |
| 700 | 1 | |a Sayón, Carmen |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin |d 1995 |g 28(2023), 5 vom: 14. Feb. |w (DE-627)NLM115683283 |x 1560-7917 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2023 |g number:5 |g day:14 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2807/1560-7917.ES.2023.28.5.2200337 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2023 |e 5 |b 14 |c 02 | ||